McGough, Kevin [MC1980]
Vice President – IP Legal at Shire
Greater Boston Area
Kevin is Vice President-IP Legal at Shire, a global biotechnology company specializing in rare diseases. He leads a team of highly skilled attorneys and is responsible for patent and transactional matters relating to Shire’s Internal Medicine, HAE, and Oncology franchises. Further, he manages worldwide patent litigations that involve these businesses, and has worked closely with corporate colleagues in various restructurings. Notably, Kevin also established and heads the first trademark group at Shire.
Shire has recognized Kevin for his operational integration of acquired companies, including the multi-billion dollar Baxalta Corporation. By introducing a new IP docketing system and streamlining administrative tasks, he has saved Shire substantial sums. Recently, his negotiation of creative outside counsel fee arrangements has saved Shire millions of dollars.
Before Shire, Kevin founded his own law firm and for thirteen years dealt with the patent aspects of a wide array of corporate acquisitions, divestitures, and licensing deals. He was recognized by Intellectual Property Law & Business magazine for his patent due diligence expertise, and he appeared as an expert witness on patent law and the Hatch-Waxman Act in Elan Pharma Int’l. Ltd., et al. v. Anchen Pharmaceuticals, Inc. and In Re Cardizem® CD Antitrust Litigation.
Previously, Kevin served as in-house counsel for Merck & Co., Inc. for thirteen years, rose to assistant counsel, and was responsible for patent and trade secret matters that were of material importance to Merck and its affiliates. Prior to Merck, Kevin was an associate attorney with the law firms of Kenyon & Kenyon and Morgan & Finnegan for 3 years.
# – # – # – # – #